Buy Geftinat 250mg online
Geftinat 250mg are used as first line therapy to treat locally advanced (stage III) or metastatic (stage IV) non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and grows more slowly than small cell lung cancer (SCLC). NSCLC is associated with a mutation in the gene for Epidermal Growth Factor Receptor (EGFR) in a proportion of these cancers1, 2 specifically those with a cell type of adenocarcinoma3. Epidermal Growth Factor is a growth factor that is found in many normal tissues and controls cell growth. However, in some types of cancer including NSLC, its action is uncontrolled, allowing cells to continue to grow and spread. For Geftinat tablets 250mg to be an effective treatment for NSCLC a specific type of gene mutation should be identified and present in the tumour cells. In these cases of treatment of NSCLC with Geftinat 250mg is highly effective in preventing disease progression.
How does Geftinat work?
Geftinat tablets 250mg contain gefitinib a potent inhibitor of tyrosine kinase (TK), an enzyme that phosphorylates a protein inside a cell (transfers a phosphate from ATP to a protein inside the cell), which is the way many cell processes are regulated. Tyrosine kinases (TK) are cell surface receptors for many cellular messengers including growth factors and gefitinib in Geftinat tablets 250mg acts as a potent inhibitor of the Epidermal Growth Factor receptor (EGFR) by targeting the part of the receptor where EGF binds to ATP (adenosine triphosphate). EGF stimulates cell growth, proliferation and differentiation in normal cells. gefitinib breast cancer acts by binding with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors. When EGF binds to EGFR, the receptor undergoes a shape change, which activates TK activity by phosphorylation of its substrates within the cell and this is the first step in a complex cell signalling pathway involved in cell proliferation and survival. Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place. However, the mutation associated with NSCLC leaves the receptor in a state that is constantly activated or turned on (constitutively activated) even when EGF is not bound to the receptor. This results in cells that are stimulated to constantly proliferate and survive leading to NSCLC.
Normally the expression of ECGFR is expressed at low levels but over expression can cause cancer and is associated with aggressive advanced and metastatic tumours as is found in 40-80% of NSCLC4. There are several different gene mutations that can affect the control of EGFR activity and gefitinib in Geftinat tablets 250mg is most effective in tumours containing the Exon 19 deletion or a L858R mutation, which is point mutations affecting a single DNA nucleotide. It has been suggested that identification of specific mutations in the ECGFR gene may predict sensitivity to gefitinib5, 6. There is also evidence of amplification of the specific mutated activating gene in some cases of NSCLC and this is thought to confer increased susceptibility to gefitinib in Geftinat tablets 250mg1. Gefitinib in Geftinat tablets 250mg works by blocking the intracellular phosphorylation of EGFR, which blocks the signalling pathway for cell proliferation and survival and induces cell death in NSCLC cells, which results in tumour regression.
What does Geftinat contain?
gefitinib benefits contain the active ingredient gefitinib 250mg, a potent inhibitor of tyrosine kinase cell surface receptor for Epidermal Growth Factor receptor (EGFR), used to treat NSCLC.
Treating non-small cell lung cancer (NSCLC) with Geftinat?
gefitinib buy contain gefitinib, a tyrosine kinase inhibitor that is used to treat NSCLC, the most common form of lung cancer. NSCLC is epithelial in origin and sub-types include adenocarcinoma, derived from the cells that line the alveoli (air sacs) making up the majority of all NSCLC (40%), squamous cell carcinoma derived from the bronchi (25-30%) and large cell undifferentiated carcinoma that can appear in any part of the lung and spreads rapidly (10-15%). NSCLC is associated with a mutation in the gene for Epidermal Growth Factor receptor (EGFR)1. Several different types of mutation have been identified and treatment of NSCLC with Geftinat tablets 250mg is only effective when a specific type of gene mutation has been identified and present in the tumour cells. Epidermal Growth Factor stimulates cell growth, proliferation and differentiation in normal cells and binds with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors. Binding of EGF to its receptor triggers the first step in a complex cell signalling pathway involved in cell proliferation and survival.
Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place. However, the mutation associated with NSCLC leaves the receptor in a state that is constantly activated or turned on (constitutively activated) even when EGF is not bound to the receptor. This results in cells that are stimulated to constantly proliferate and survive leading to NSCLC. Gefitinib in Geftinat tablets 250mg works by blocking the intracellular signalling pathway for cell proliferation and survival, thereby inhibiting the proliferation of the tumour cells and reinstating programmed cell death, which results in tumour regression.
What are the side effects of Geftinat?
Geftinat most commonly reported side effects when taking Geftinat tablets 250mg side effects include, ausea, vomiting, diarrhoea, abdominal pain, loss of appetite with anorexia, rash, dry or cracked skin, nail problems, fatigue (asthenia), fever, increased bleeding including nosebleeds (epistaxis) and blood in the kidney (haematuria), eye disorders, including irritation of the cornea (keratitis), conjunctivitis, blepharitis (inflammation of the eyelids) and dry eyes. Persistent diarrhoea may lead to dehydration, potassium depletion and impaired kidney function. A more serious but common side effect is interstitial lung disease (a serious inflammation of the lungs with possible scarring).
What medications interact with Geftinat?
Several medications interact with Geftinat tablets 250mg and should either not be taken while you are taking Geftinat or only after discussion and instruction from your doctor: Drugs that cause a serious reaction with Geftinat: corticosteroids and NSAIDs can increase risk of gastrointestinal perforation; anticoagulants like warfarin cause increased bleeding
Drugs that affect Geftinat: verapamil for hypertension, proton pump inhibitors like omeprazole, antifungals like ketoconazole, antibiotics like ciprofloxacin, erythromycin, clarithromycin, rifampicin, anticonvulsants like phenytoin, carbamazepine, ranitidine for reflux, St. John’s Wort
How should Geftinat be taken?
You should take your Geftinat tablets 250mg swallowed whole with a glass of water once daily with or without food. Geftinat 250mg dose you take and for how long depends on your doctor’s recommendation and you should continue to take your Geftinat tablets 250mg for as long as recommended by your doctor.
How long should you take Geftinat?
You should continue to take your Geftinat tablets 250mg for as long as recommended by your doctor.
If you miss a dose of Geftinat tablets 250mg take it as soon as you remember, unless it is time to take the next dose, then skip the missed dose. Do not take a double dose.
How should Geftinat be stored?
You should store your Geftinat tablets 250mg below 25°C in a cool dry place.